Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy
where T lymphocytes are engineered with synthetic receptors known as chimeric antigen …

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a
wide variety of human tumors. For many years, apoptosis has been considered a non …

Many cancer types metastasize to bone. This propensity may be a product of genetic traits of
the primary tumour in some cancers. Upon arrival, cancer cells establish interactions with …

Despite advances in treatment for multiple myeloma, the majority of patients ultimately
develop relapsed disease marked by immune evasion and resistance to standard therapy …

Multiple myeloma (MM) is characterized by the clonal proliferation of malignant plasma cells
and refractoriness to traditional therapies. It has been shown that exosomes are involved in …

Multiple myeloma (MM) is a distinguished hematologic malignancy, with existing studies
elucidating its interaction with neutrophil extracellular traps (NETs), which may potentially …

The past two decades have seen a revolution in multiple myeloma (MM) therapy with the
introduction of several small molecules, mostly orally effective, whose mechanisms are …

The treatment landscape of multiple myeloma (MM) has evolved considerably with the FDA-
approval of at least 15 drugs over the past two decades. Together with the use of autologous …

Despite many recent advances on cancer novel therapies, researchers have yet a long way
to cure cancer. They have to deal with tough challenges before they can reach success …